本文件描述了由德国核医学学会(DGN)发布并被德国科学医学协会(AWMF)接受的肽受体放射性核素治疗(PRRT)的指南,该指南将包含在官方的AWMF指南注册中。这些建议是使用PRRT治疗生长抑素受体表达肿瘤患者的质量管理的先决条件。它们旨在指导核医学专家选择可能的候选人接受PRRT并以安全有效的方式提供治疗。这些建议是基于跨学科的共识。该文件包含背景信息和定义,并涵盖了基本原理,PRRT的适应症和禁忌症。基本主题是对进行治疗的机构的要求,例如,有医学物理学专家在场,与所有参与治疗患者的同事密切合作,并需要放射化学标签和质量控制的指导证书。此外,规定了在进行治疗之前必须提供哪些患者数据,以及技术上必须如何进行治疗。这里,标签的质量控制和文件编制非常重要。治疗后,临床质量控制是强制性的(治疗数据的整理和患者的随访).详细说明了后续行动的基本要素。必须与所涉及的医学学科密切合作,才能实现完整的包容性治疗。一般来说,PRRT的决定应在多学科肿瘤委员会的框架内进行.
This document describes the
guideline for peptide receptor radionuclide therapy (PRRT) published by the German Society of Nuclear Medicine (DGN) and accepted by the Association of the Scientific Medical Societies in Germany (AWMF) to be included in the official AWMF
Guideline Registry. These recommendations are a prerequisite for the quality management in the treatment of patients with somatostatin receptor expressing tumours using PRRT. They are aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRT and to deliver the treatment in a safe and effective manner. The recommendations are based on an interdisciplinary
consensus. The document contains background information and definitions and covers the rationale, indications and contraindications for PRRT. Essential topics are the requirements for institutions performing the therapy, e. g. presence of an expert for medical physics, intense cooperation with all colleagues involved in the treatment of a patient, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with the involved medical disciplines. Generally, the decision for PRRT should be undertaken within the framework of a multi-disciplinary tumour board.